Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says
08.04.2026 15:06
Gilead Sciences (GILD) agreed to acquire Tubulis for $5 billion, its "third takeout" in six weeks as
Gilead Sciences Is Doubling Down On Acquisitions
08.04.2026 08:00
Gilead Sciences' recent acquisitions do not materially alter the investment thesis or valuation. Click here to see why GILD stock is a Hold.
Is Gilead Sciences (GILD) Among the Best Low Volatility Blue Chip Stocks to Buy Now?
08.04.2026 05:05
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Low Volatility Blue Chip Stocks to Buy Now. On April 7, Leerink reiterated an Outperform rating on Gilead Sciences, Inc. (NASDAQ:GILD), after the company announced a definitive agreement to acquire privately held Tubulis in a deal valued at up to $5 billion. The firm views […]
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript
08.04.2026 00:06
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion April 7, 2026 4:30 PM EDTCompany...
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
07.04.2026 12:50
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.
Gilead to acquire Tubulis GmbH for up to $5 billion
07.04.2026 12:39
April 7 () - Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, as the U. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
07.04.2026 12:30
FOSTER CITY, Calif. & MUNICH, April 07, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead’s oncology pipeline, focused on addressing areas of high unmet need.
ValuEngine Weekly Market Summary And Commentary
07.04.2026 06:05
US equities continued their upward momentum over last week, with broad-based gains across major sectors led by tech, industrials, and small-caps. The energy sector was the notable exception.
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
01.04.2026 14:06
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
01.04.2026 11:05
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each offering a differentiated mechanism, commercial traction, or platform technology that a deep-pocketed acquirer would find difficult to replicate organically. Incyte Incyte (NASDAQ: INCY) ... 5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heat
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
31.03.2026 08:16
Gilead Sciences (NasdaqGS:GILD) has entered a definitive agreement to acquire Ouro Medicines, expanding into T cell engager therapies for autoimmune diseases. The company has also signed a collaboration agreement with Galapagos NV to advance T cell engager therapies. These moves affect Gilead's research pipeline and potential future treatment offerings. Gilead Sciences, trading at $136.34, has seen a 12.1% return year to date and a 24.9% return over the past year. Over 3 years, the stock...
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
31.03.2026 05:30
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks
28.03.2026 03:50
Gilead Sciences has experienced a significant valuation re-rating, now trading at 16-17x earnings after doubling from 2024 lows. Read why GILD stock is a hold.
Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade)
27.03.2026 16:48
Gilead Sciences, Inc. now a Hold after a rally to ~$138. See valuation, HIV strength, Trodelvy upside, M&A risks, and $98â$209 range. Click for this GILD update.
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
27.03.2026 13:30
The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
27.03.2026 12:49
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.
European stocks close lower as Trump extends Iran strike hiatus and G7 ministers meet
27.03.2026 03:19
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
27.03.2026 00:55
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 23, The Wall Street Journal reported that Gilead Sciences, Inc. (NASDAQ:GILD) plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. The company also intends to develop the acquired […]
Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout
24.03.2026 17:32
This atypical deal structure will see Gilead collaborate with Galapagos to develop gamgertamig for the treatment of B-cell mediated autoimmune diseases.
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio
24.03.2026 14:25
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotech company developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3...